1. 1. A diagnosing health care provider or an administrator of a health care institution, either personally or through a representative, shall isolate and implement contact precautions for a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus.
2. 2. A diagnosing health care provider or an administrator of a health care institution transferring a known case with active infection or a known carrier of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus to another health care provider or health care institution shall, either personally or through a representative, comply with R9-6-305.

3. 3. A local health agency, in consultation with the Department, shall:

   1. a. Upon receiving a report of a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus, notify the Department within one working day after receiving the report and provide to the Department the information contained in the report;
   2. b. Ensure that a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus is isolated as necessary to prevent transmission;
   3. c. Conduct an epidemiologic investigation of each reported case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus;
   4. d. For each case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus, submit to the Department, as specified in Table 2.4, the information required under R9-6-206(D); and
   5. e. In consultation with the Department, ensure that an isolate or a specimen, as available, from each case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus is submitted to the Arizona State Laboratory.

Case control measures:

Historical Note

New Section R9-6-3101 renumbered from R9-6-391 and amended by final rulemaking at 31 A.A.R. 1317 (April 25, 2025), effective June 2, 2025 (Supp. 25-2).